APPENDIX TO AD 98–23–01; DOCKET NO. 98–CE–108–AD—Continued

Part name	Part No.	Airplane/engine make/model
		ENGINES
		Textron Lycoming / LIO–360, GO–435, TIO–541.
		Continental / E–185, E–225, IO–346, O–470, IO–470, TSIO–470, IO–520.
		Franklin / 6A–335, 6A–350.
Conversion Kit	300–1	Cessna / 172A, 172B thru 172H.
		Piper / PA–22–108, PA–22–135, PA–22S–135, PA–22–150, PA–22S–150, PA–22–160, PA–22S–160.
Conversion Kit	300–2	Beech / 35 thru S35, 35–33 thru 35–A33, 35–B33.
		Cessna / 175 thru 175A, 175B, 175C, P172D, 180 thru 180H, 182 thru 182H, 185 thru 185D, 210, 210A thru 210J, 210–5, 210–5A.
Conversion Kit	300–3	Cessna / 150, 150A thru 150H.
Coupling Kit	350	Coupling kit may have been put on any of the above list airplanes or engines.

Issued in Kansas City, Missouri, on November 4, 1998.

James E. Jackson,

Acting Manager, Small Airplane Directorate, Aircraft Certification Service.

[FR Doc. 98–30170 Filed 11–16–98; 8:45 am]

BILLING CODE 4910–13–P

DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration

14 CFR Parts 91, 121, and 125

[Docket No. 28537; SFAR 50–2]

Special Flight Rules in the Vicinity of Grand Canyon National Park

AGENCY: Federal Aviation Administration (FAA), DOT.

ACTION: Final rule; correcting amendment; correction.

SUMMARY: This document contains a correction to the final rule published in the **Federal Register** (63 FR 23604) on April 29, 1998. The final rule corrected an error in the February 26, 1997, final rule, which inadvertently removed section 3 of SFAR No. 50–2 concerning special flight rules in the vicinity of Grand Canyon National Park. The April 1998 final rule corrected the error by reinstating section 3.

EFFECTIVE DATE: November 17, 1998.

FOR FURTHER INFORMATION CONTACT: David L. Catey, (202) 267–8166.

Correction of Publication

In final rule FR Doc. 98–11335, on page 23604 in the **Federal Register** issue of April 29, 1998, make the following corrections:

On page 23604, in the first column, in the heading, ''14 CFR Parts 91, 93, 121, and 135'' should read ''14 CFR Parts 91, 121, and 135''.

On page 23604, in the first column, in the heading, ''[Docket No. 28537; Amendment Nos. 91–257, 121–270, 135–72, 93–76]'' should read ''[Docket No. 28437; SFAR 50–2]''.

Issued in Washington, DC, on November 4, 1998.

Donald P. Byrne,

Assistant Chief Counsel.

[FR Doc. 98–30090 Filed 11–16–98; 8:45 am]

BILLING CODE 4910–13–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Part 522

Implantation or Injectable Dosage Form New Animal Drugs; Trenbolone Acetate and Estradiol Benzoate

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule.

SUMMARY: The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of a supplemental new animal drug application (NADA) filed by Fort Dodge Animal Health, Division of American Home Products Corp. The supplemental NADA provides for the use of a trenbolone acetate and estradiol benzoate ear implant in heifers fed in confinement for slaughter for increased rate of weight gain.

EFFECTIVE DATE: November 17, 1998.

FOR FURTHER INFORMATION CONTACT: Jack Caldwell, Center for Veterinary Medicine (HFV–126), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–827–0217.

SUPPLEMENTARY INFORMATION: Fort Dodge Animal Health, Division of American Home Products Corp., 800 Fifth St. NW., Ft. Dodge, IA 50501, filed supplemental NADA 141–043 that provides for use of an implantation containing 200 milligrams (mg) trenbolone acetate and 28 mg estradiol benzoate (Synovex® Plus) in heifers fed in confinement for slaughter for increased rate of weight gain. The supplemental NADA is approved as of September 30, 1998, and the regulations are amended in 21 CFR 522.2478 by adding paragraph (c)(2) to reflect the approval. The basis for approval is discussed in the freedom of information summary.

–In accordance with the freedom of information provisions of 21 CFR part 20 and 514.11(e)(2)(ii), a summary of safety and effectiveness data and information submitted to support approval of this application may be seen in the Dockets Management Branch (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday.

Under section 512(c)(2)(F)(iii) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360b(c)(2)(F)(iii)), this approval for food producing animals qualifies for 3 years of marketing exclusivity beginning September 30, 1998, because the supplemental application contains substantial evidence of the effectiveness of the drug involved, any studies of animal safety, or, in the case of food producing animals, human food safety studies (other than bioequivalence or residue studies) required for the approval of the supplement and conducted or sponsored by the applicant. The 3 years of marketing exclusivity applies only to use in confined heifers for increased rate of weight gain for which the supplemental application is approved.

The agency has determined under 21 CFR 25.33(a)(1) that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.

List of Subjects in 21 CFR Part 522

Animal drugs.

–Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to